Trimebutine 3-thiocarbamoylbenzenesulfonate

Drug Profile

Trimebutine 3-thiocarbamoylbenzenesulfonate

Alternative Names: GIC-1001; TB-905-02

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antibe Therapeutics
  • Developer gIcare Pharma
  • Class Antispasmodics; Benzenesulfonates; Benzoic acids; Irritable bowel syndrome therapies; Opioid analgesics; Organic sulfur compounds; Phenylbutyrates
  • Mechanism of Action Muscarinic receptor antagonists; Neurotransmitter modulators; Opioid kappa receptor agonists; Opioid mu receptor agonists; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Irritable bowel syndrome; Procedural pain

Most Recent Events

  • 17 Feb 2016 No recent reports on development identified - Phase-II for Procedural pain in USA and Canada (PO)
  • 17 Feb 2016 No recent reports on development identified - Preclinical for Irritable bowel syndrome in Canada (PO)
  • 01 Dec 2014 gIcare Pharma completes a phase Ib trial in healthy volunteers in Canada (NCT02276768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top